Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 387
- 主要终点
- Intraocular Pressure (IOP) at Baseline
研究概览
简要总结
This study will assess the efficacy, safety, tolerability and persistence of use of Lumigan ® 0.01% in patients diagnosed with primary open-angle glaucoma or ocular hypertension who are treated per routine clinical practice.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of primary open-angle glaucoma or ocular hypertension
- •Lumigan® 0.01% prescribed either as monotherapy or adjunctive to beta-blocker therapy
排除标准
- 未提供
研究组 & 干预措施
Lumigan® 0.01%
Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.
干预措施: bimatoprost 0.01% ophthalmic solution (Drug)
结局指标
主要结局
Intraocular Pressure (IOP) at Baseline
时间窗: Baseline
IOP is a measurement of the fluid pressure inside the eye. IOP was measured in the left and right eye at Baseline.
Intraocular Pressure (IOP) at Week 12
时间窗: Week 12
IOP is a measurement of the fluid pressure inside the eye. IOP was measured in the left and right eye at the Final Visit at approximately Week 12. The lower the IOP values the greater the improvement.
次要结局
- Patient Evaluation of Tolerability of Treatment Using a 4-Point Scale(Week 12)
- Physician Evaluation of Tolerability of Treatment(Week 12)
- Physician Reported Reasons for Early Discontinuation of Treatment(12 Weeks)
- Physician Evaluation of Efficacy Using a 5-Point Scale(Week 12)
- Number of Patients Continuing Treatment After 12 Weeks(Week 12)